Behavioral and Cognitive Therapies for Auditory Hallucination Management
AcceptVoice
2 other identifiers
interventional
55
1 country
5
Brief Summary
The present study wants to evaluate the efficacy of a short psychoeducational type group intervention and Cognitive behavioral therapy (CBT) 3rd wave on the severity of hallucinatory Acoustico-Verbal (HAV) symptomatology in patients with schizophrenia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Dec 2017
Typical duration for not_applicable
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 14, 2017
CompletedFirst Posted
Study publicly available on registry
November 21, 2017
CompletedStudy Start
First participant enrolled
December 13, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 5, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2020
CompletedJuly 30, 2020
July 1, 2020
2 years
November 14, 2017
July 29, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
intensity HAV symptoms
Difference between the Psychotic Symptom Rating Scales (PSYRATS) on HAV symptom score administered before the first therapeutic group session and the PSYRATS symptom score administered 1 week after the last group session. The PSYRATS Scales measure dimensions of hallucinations and delusions.
Baseline and one week after the last session
Secondary Outcomes (1)
Effect over time
Until 12 months after the last session
Study Arms (1)
Behavioral and Cognitive Therapies
EXPERIMENTALChronic psychotic patients will have Behavioral and Cognitive Therapies
Interventions
Group intervention of 6 weekly sessions of one hour and 30 minutes based on the psychoeducational therapeutic principles and CBT type 3 wave "Accept Voices" applied to HAV
Eligibility Criteria
You may qualify if:
- Schizophrenic disorders, schizo-affective disorders
- Suffering from persistent HAV
- No change in symptomatology for 3 months.
- No anticipated change in antipsychotic treatment (anti-hallucinatory): olanzapine, risperidone, amisulpride, quetiapine, aripiprazole, loxapine, haloperidol, clopixol, modecate, nozinan, cyamemazine, piportil, clozapine
- Major patient, or major incompetent.
You may not qualify if:
- Mental retardation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (5)
Lannemezan Hospital
Lannemezan, 65300, France
Lavaur Hospital
Lavaur, 81502, France
Sainte-Marie de Rodez Hospital
Rodez, 12032, France
Ariège-Couserans Hospital
Saint-Lizier, 09190, France
Gérard Marchand Hospital
Toulouse, 31057, France
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Axel Bourcier, PhD
University Hospital, Toulouse
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 14, 2017
First Posted
November 21, 2017
Study Start
December 13, 2017
Primary Completion
December 5, 2019
Study Completion
June 30, 2020
Last Updated
July 30, 2020
Record last verified: 2020-07
Data Sharing
- IPD Sharing
- Will not share